COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting May 23, 2022
Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted… May 16, 2022
Two Thirds Of Physicians Surveyed Believe Psilocybin Therapy Has Potential Benefit For Patients With Treatment-Resistant… Jan 19, 2022
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Sep 14, 2021
Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104 Sep 9, 2021
